Correction: Garza-Morales et al. Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. Cancers 2018, 10, 144
by
,
Rodolfo Garza-Morales
1,2,†
,
Roxana Gonzalez-Ramos
1,†,
Akiko Chiba
3,
Roberto Montes de Oca-Luna
2,
Lacey R. McNally
4,
Kelly M. McMasters
1,5 and
Jorge G. Gomez-Gutierrez
1,5,* 1
The Hiram C. Polk Jr., MD, Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40202, USA
2
Department of Histology, School of Medicine, Autonomous University of Nuevo Leon, Monterrey 64460, NL, Mexico
3
Department of Surgery, School of Medicine, Wake Forest University, Winston-Salem, NC 27109, USA
4
Department of Cancer Biology, Wake Forest Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC 27109, USA
5
James Graham Brown Cancer Center, School of Medicine, University of Louisville, Louisville, KY 40202, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this study.
Cancers 2024, 16(7), 1432; https://doi.org/10.3390/cancers16071432
Submission received: 14 March 2024
/
Accepted: 15 March 2024
/
Published: 7 April 2024
Error in Figure
In the original publication [1], there was a mistake in the right side of Figure 1A. The image of a crystal violet plate of MDA-MB-231 cells was inadvertently duplicated from a previous manuscript (reference [27] in original publication [1]). The corrected Figure 1A and its quantification have been updated in the figure below. A new set of experiments was performed to replace the duplicated crystal violet plate and generate a new quantification graph. The authors apologize for any inconvenience caused and state that the scientific conclusions remained unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Garza-Morales, R.; Gonza-lez-Ramos, R.; Chiba, A.; de Oca-Luna, R.M.; McNally, L.R.; McMasters, K.M.; Gomez-Gutierrez, J.G. Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. Cancers 2018, 10, 144. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Oncolytic adenovirus expressing mCherry (OAdmCherry) and temozolomide (TMZ) have a cell-killing effect on human triple-negative breast cancer (TNBC) cells: (A) HCC1937 and MDA-MB-231 cells were infected with OAdmCherry or adenovirus expressing green fluorescent protein (AdGFP) at different multiplicity of infection concentrations for 72 h. Crystal violet staining was used to evaluate cytopathic effect (CPE). A representative staining of three independent experiments is shown. (B) Relative cell survival was calculated by measuring the absorbance of solubilized dye at 590 nm. (C) HCC1937 and MDA-MB-231 cells were treated with TMZ at different concentrations for 72 h. Cell survival was calculated by MTT assay. Results represent the mean of three repeated measurements ± standard deviation (SD; error bars) (* p < 0.05).
Figure 1.
Oncolytic adenovirus expressing mCherry (OAdmCherry) and temozolomide (TMZ) have a cell-killing effect on human triple-negative breast cancer (TNBC) cells: (A) HCC1937 and MDA-MB-231 cells were infected with OAdmCherry or adenovirus expressing green fluorescent protein (AdGFP) at different multiplicity of infection concentrations for 72 h. Crystal violet staining was used to evaluate cytopathic effect (CPE). A representative staining of three independent experiments is shown. (B) Relative cell survival was calculated by measuring the absorbance of solubilized dye at 590 nm. (C) HCC1937 and MDA-MB-231 cells were treated with TMZ at different concentrations for 72 h. Cell survival was calculated by MTT assay. Results represent the mean of three repeated measurements ± standard deviation (SD; error bars) (* p < 0.05).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Garza-Morales, R.; Gonzalez-Ramos, R.; Chiba, A.; Montes de Oca-Luna, R.; McNally, L.R.; McMasters, K.M.; Gomez-Gutierrez, J.G. Correction: Garza-Morales et al. Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. Cancers 2018, 10, 144. Cancers 2024, 16, 1432. https://doi.org/10.3390/cancers16071432
AMA Style
Garza-Morales R, Gonzalez-Ramos R, Chiba A, Montes de Oca-Luna R, McNally LR, McMasters KM, Gomez-Gutierrez JG. Correction: Garza-Morales et al. Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. Cancers 2018, 10, 144. Cancers. 2024; 16(7):1432. https://doi.org/10.3390/cancers16071432
Chicago/Turabian StyleGarza-Morales, Rodolfo, Roxana Gonzalez-Ramos, Akiko Chiba, Roberto Montes de Oca-Luna, Lacey R. McNally, Kelly M. McMasters, and Jorge G. Gomez-Gutierrez. 2024. "Correction: Garza-Morales et al. Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. Cancers 2018, 10, 144" Cancers 16, no. 7: 1432. https://doi.org/10.3390/cancers16071432
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
